
    
      Amendment 4 unblinded treatment after an interim analysis for all subsequently enrolled TN
      participants (the Second Cohort) who were receiving grazoprevir 400 or 800 mg daily, and they
      were down-dosed to 100 mg daily between Treatment Week (TW) 3 and TW12 for the remainder of
      the 12-week treatment course.

      Amendment 5 allowed treatment-na√Øve participants with chronic hepatitis C and compensated
      cirrhosis to be enrolled and receive open-label grazoprevir 100 mg in combination with
      Peg-IFN and RBV, without a corresponding control arm.
    
  